Delivering What Matters to Biopharma
Ophthalmic clinical trials require exceptional rigor due to the complexity of eye anatomy, specialized drug formulations, and precise diagnostic assessments.
At GCP ClinPlus, we offer tailored ophthalmology trial solutions—from early-phase feasibility through to registration and post-marketing studies.
Our strengths lie in both conventional ophthalmic therapies and advanced cell & gene therapies (CGT), particularly for rare genetic eye diseases such as retinitis pigmentosa, achromatopsia, Leber congenital amaurosis (LCA), and Leber hereditary optic neuropathy (LHON).
We have built a robust operational infrastructure, including:
Rapid-response protocol design and flexible project execution
Accelerated study start-up with ophthalmology-trained teams
A full-service medical team with ophthalmology MDs supporting clinical oversight
GCP ClinPlus has supported more than 40 ophthalmology studies, working with both domestic and international sponsors, including Kanghong, Bausch + Lomb, and Santen.
Whether your focus is age-related macular degeneration, diabetic retinopathy, glaucoma, cataracts, or ophthalmic devices, our experienced team ensures accuracy, speed, and regulatory readiness throughout the trial lifecycle.
